

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM S-8  
REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933**

---

**STOKE THERAPEUTICS, INC.**

(Exact name of Registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**47-1144582**  
(I.R.S. Employer  
Identification Number)

**45 Wiggins Avenue  
Bedford, MA 01730  
(781)-430-8200**  
(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**2019 Equity Incentive Plan  
2019 Employee Stock Purchase Plan**  
(Full title of the plans)

**Edward M. Kaye, M.D.  
Chief Executive Officer  
Stoke Therapeutics, Inc.  
45 Wiggins Avenue  
Bedford, MA 01730  
(781)-430-8200**  
(Telephone number, including area code, of agent for service)

*Please send copies of all communications to:*

**Robert A. Freedman, Esq.  
Julia Forbess, Esq.  
Fenwick & West LLP  
555 California Street, 12th Floor  
San Francisco, California 94104  
(415) 875-2300**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer   
Non-accelerated filer  Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

---

## REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

Pursuant to General Instruction E of Form S-8, Stoke Therapeutics, Inc. (the “**Registrant**”) is filing this Registration Statement with the Securities and Exchange Commission (the “**Commission**”) to register 1,836,729 additional shares of Common Stock under the Registrant’s 2019 Equity Incentive Plan (“**EIP**”), pursuant to the provisions of the EIP providing for an automatic increase in the number of shares reserved for issuance under the EIP, and 459,182 additional shares of Common Stock under the Registrant’s 2019 Employee Stock Purchase Plan (“**ESPP**”), pursuant to the provisions of the ESPP providing for an automatic increase in the number of shares reserved for issuance under the ESPP. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statements on Form S-8 filed with the Commission on June 19, 2019 (Registration No. [333-232191](#)), March 23, 2020 (Registration Statement No. [333-237345](#)), March 19, 2021 (Registration Statement No. [333-254499](#)), March 14, 2022 (Registration Statement No. [333-263531](#)) and March 22, 2023 (Registration Statement No. [333-270744](#)). In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

**PART II**  
**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”), are incorporated herein by reference:

- (a) the Registrant’s Annual Report on [Form 10-K](#) for the fiscal year ended December 31, 2023, filed with the Commission on March 25, 2024;
- (b) all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and
- (c) the description of the Registrant’s common stock contained in the Registrant’s registration statement on [Form 8-A](#) (File No. 001-38938) filed with the Commission on June 11, 2019 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

**Item 8. Exhibits.**

The following exhibits are filed herewith:

Exhibit Number	Exhibit Description	Incorporated by Reference				Filed Herewith
		Form	File No.	Exhibit	Filing Date	
4.1	<a href="#">Restated Certificate of Incorporation of the Registrant, as amended</a>	10-K	001-38938	3.1	3/25/2024	
4.2	<a href="#">Restated Bylaws of the Registrant</a>	8-K	001-38938	3.1	2/3/2023	
4.3	<a href="#">Form of Registrant's Common Stock certificate</a>	S-1/A	333-231700	4.1	6/7/2019	
5.1	<a href="#">Opinion of Fenwick &amp; West LLP</a>					X
23.1	<a href="#">Consent of Fenwick &amp; West LLP (contained in Exhibit 5.1)</a>					X
23.2	<a href="#">Consent of Independent Registered Public Accounting Firm</a>					X
24.1	<a href="#">Power of Attorney (included on the signature page to this Registration Statement)</a>					X
99.1	<a href="#">2019 Equity Incentive Plan and forms of award agreements thereunder</a>	10-K	001-38938	10.3	3/6/2023	
99.2	<a href="#">2019 Employee Stock Purchase Plan and forms of award agreements thereunder</a>	S-1/A	333-231700	10.5	6/7/2019	
107.1	<a href="#">Filing Fee Table</a>					X

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedford, State of Massachusetts, on this 11th day of April, 2024.

**STOKE THERAPEUTICS, INC.**

By: /s/ Edward M. Kaye  
Edward M. Kaye, M.D.  
*Chief Executive Officer*

## POWER OF ATTORNEY

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below hereby constitutes and appoints Edward M. Kaye and Stephen J. Tulipano, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the date indicated.

<u>Name</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Edward M. Kaye</u> Edward M. Kaye, M.D.	Chief Executive Officer and Director (Principal Executive Officer)	April 11, 2024
<u>/s/ Stephen J. Tulipano</u> Stephen J. Tulipano	Chief Financial Officer (Principal Financial and Accounting Officer)	April 11, 2024
<u>/s/ Jennifer C. Burstein</u> Jennifer C. Burstein	Director	April 11, 2024
<u>/s/ Seth L. Harrison</u> Seth L. Harrison, M.D.	Director	April 11, 2024
<u>/s/ Adrian R. Krainer</u> Adrian R. Krainer, Ph.D.	Director	April 11, 2024
<u>/s/ Arthur A. Levin</u> Arthur A. Levin, Ph.D.	Director	April 11, 2024
<u>/s/ Garry E. Menzel</u> Garry E. Menzel, Ph.D.	Director	April 11, 2024
<u>/s/ Ian F. Smith</u> Ian F. Smith	Director	April 11, 2024
<u>/s/ Julie Anne Smith</u> Julie Anne Smith	Director	April 11, 2024
<u>/s/ Arthur O. Tzianabos</u> Arthur O. Tzianabos, Ph.D.	Director	April 11, 2024



555 California Street  
12th Floor  
San Francisco, CA 94104

415.875.2300  
Fenwick.com

April 11, 2024

Stoke Therapeutics, Inc.  
45 Wiggins Avenue  
Bedford, Massachusetts 01730

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

As counsel to Stoke Therapeutics, Inc., a Delaware corporation (the "**Company**"), we have examined the Registration Statement on Form S-8 (the "**Registration Statement**") to be filed by the Company with the Securities and Exchange Commission (the "**Commission**") on or about April 11, 2024 in connection with the registration under the Securities Act of 1933, as amended (the "**Securities Act**"), of an aggregate of 2,295,911 shares (the "**Shares**") of the Company's Common Stock, \$0.0001 par value per share (the "**Common Stock**"), subject to issuance by the Company upon the exercise or settlement of awards granted or to be granted under the 2019 Equity Incentive Plan (the "**2019 Plan**") and pursuant to purchase rights to acquire shares of Common Stock granted or to be granted under the Company's 2019 Employee Stock Purchase Plan (the "**Purchase Plan**"). The 2019 Plan and the Purchase Plan are collectively referred to as the "**Plans**."

As to matters of fact relevant to the opinions rendered herein, we have examined such documents, certificates and other instruments which we have deemed necessary or advisable, including a certificate addressed to us and dated the date hereof executed by the Company (the "**Opinion Certificate**"). We have not undertaken any independent investigation to verify the accuracy of any such information, representations or warranties or to determine the existence or absence of any fact, and no inference as to our knowledge of the existence or absence of any fact should be drawn from our representation of the Company or the rendering of the opinion set forth below. We have not considered parol evidence in connection with any of the agreements or instruments reviewed by us in connection with this letter.

In our examination of documents for purposes of this letter, we have assumed, and express no opinion as to, the genuineness and authenticity of all signatures on original documents, the authenticity and completeness of all documents submitted to us as originals, that each document is what it purports to be, the conformity to originals of all documents submitted to us as copies or facsimile copies, the absence of any termination, modification or waiver of or amendment to any document reviewed by us (other than as has been disclosed to us), the legal competence or capacity of all persons or entities (other than the Company) executing the same and (other than the Company) the due authorization, execution and delivery of all documents by each party thereto. We have also assumed the conformity of the documents filed with the Commission via the Electronic Data Gathering, Analysis and Retrieval System ("**EDGAR**"), except for required EDGAR formatting changes, to physical copies submitted for our examination.

The opinions in this letter are limited to the existing General Corporation Law of the State of Delaware now in effect. We express no opinion with respect to any other laws.

Based upon, and subject to, the foregoing, it is our opinion that the Shares, when issued and sold by the Company in accordance with the terms (including, without limitation, payment and authorization provisions) of the applicable Plan and the applicable form of award agreement thereunder, against the Company's receipt of payment therefor (in an amount and type of consideration not less than the par value per Share), and duly registered on the books of the transfer agent and registrar for the Shares in the name or on behalf of the holders thereof, will be validly issued, fully paid and non-assessable.

We consent to the use of this opinion as an exhibit to the Registration Statement and further consent to all references to us, if any, in the Registration Statement, the prospectuses constituting a part thereof and any amendments thereto. We do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

This opinion is intended solely for your use in connection with the issuance and sale of the Shares subject to the Registration Statement and is not to be relied upon for any other purpose. In providing this letter, we are opining only as to the specific legal issues expressly set forth above, and no opinion shall be inferred as to any other matter or matters. This opinion is rendered on, and speaks only as of, the date of this letter first written above, and does not address any potential change in facts or law that may occur after the date of this opinion letter. We assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that may hereafter be brought to our attention, whether or not such occurrence would affect or modify any of the opinions expressed herein.

Sincerely,

/S/ FENWICK & WEST LLP

FENWICK & WEST LLP



**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated March 25, 2024, with respect to the consolidated financial statements of Stoke Therapeutics, Inc., incorporated herein by reference.

/s/ KPMG LLP

Boston, Massachusetts  
April 11, 2024

## CALCULATION OF FILING FEE TABLES

**Form S-8**  
(Form Type)

**Stoke Therapeutics, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1 – Newly Registered Securities**

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered(1)	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common stock, par value \$0.0001 per share	Rule 457(c) and Rule 457(h)	1,836,729(2)	\$12.33 (3)	\$22,646,869	\$0.0001476	\$3,343
Equity	Common stock, par value \$0.0001 per share	Rule 457(c) and Rule 457(h)	459,182(4)	\$10.49 (5)	\$4,816,820	\$0.0001476	\$711
<b>Total Offering Amounts</b>					\$27,463,689		\$4,054
<b>Total Fee Offsets</b>							—
<b>Net Fee Due</b>							\$4,054

- (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “*Securities Act*”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock, par value \$0.0001 per share (the “*Common Stock*”) that becomes issuable in respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration that increases the number of the Registrant’s outstanding shares of Common Stock.
- (2) Represents additional shares of Common Stock reserved for issuance under the Registrant’s 2019 Equity Incentive Plan (the “*2019 EIP*”).
- (3) Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of \$12.33, the average of the high and low prices of the Registrant’s Common Stock as reported on The Nasdaq Global Select Market on April 5, 2024.
- (4) Represents additional shares of Common Stock reserved for issuance under the Registrant’s 2019 Employee Stock Purchase Plan (the “*2019 ESPP*”).
- (5) Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of \$10.49, the average of the high and low prices of the Registrant’s Common Stock as reported on The Nasdaq Global Select Market on April 5, 2024, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2019 ESPP.